



Patient Information	Physician Information	Sample Information
PPBRS, Sample Age/Sex: 52/M DOB: 02/15/1972	Dr. TEST, Sample Location Address Line 1 City, CA 12345 Phone : 999.123.4567 Fax : 999.123.4568	Accession#: TEDXPBRS24-00025 Date Collected: 11/04/2024 Date Received: 11/05/2024 Date Reported: 11/05/2024 Specimen: Rectal Swab ICD 10: R97.20

Results: Positive

ORGANISM(S) - DETECTED

- Enterobacter cloacae 86%
- Escherichia coli 14%
- Actinobaculum schaalii < 1%
- Coagulase negative Staphylococcus** < 1%

Report Key	Cefixime	Ciprofloxacin	Levofloxacin	Ofloxacin	Sulfamethoxazole/Trimethoprim	Tetracycline	Amikacin	Gentamicin	Tobramycin	Ceftriaxone	Imipenem	Meropenem	Cefepime	Ceftazidime / Avibactam	Nitrofurantoin	Piperacillin / Tazobactam	Amoxicillin / Clavulanate	Ampicillin	Cefaclor	Doxycycline	Cefotaxime	Aztreonam	Cefazolin	Cefoxitin	Penicillin G	Vancomycin	
RGD = Resistance Gene(s) Detected S = Sensitivity Detected R = Resistance Detected N = No Reference																											
Formulation	PO	PO/IV	PO/IV	PO	PO/IV	PO	IV/IM	IM/IV	IM/IV	IM/IV	IV	IV	IV	IV	PO	IV	PO	PO/IV	PO	PO/IV	PO/IV	PO/IV	PO/IV	PO/IV	PO/IV	PO/IV	
Sensitivity result:																											
Enterobacter cloacae	S	S	S	S	S	S	S	S	S	S	S	S	S	S	N	N	R	R	R	S	R	R	R	R	S	S	
Escherichia coli	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	R	S	S	S	S	R	R	
Resistant Gene result :	RGD	RGD	RGD	RGD	RGD			RGD	RGD	RGD			RGD					RGD	RGD	RGD			RGD	RGD	RGD		
Organism(s) Tested-Detected: + = Plus marks are supportive data and are NOT patient specific																											
Actinobaculum schaalii		+	+			+		+		+					+			+			+					+	
Coagulase negative Staphylococcus**		+	+			+				+	+	+	+		+	+	+		+		+		+			+	
Enterobacter cloacae		+	+	+	+			+	+		+	+	+	+		+											
Escherichia coli	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+				+	+	+	+			

Information about the table:
 Green PlusMarks + indicate there is supportive evidence that the antibiotic either FDA approved or off label can be used for treatment. PlusMark treatment options are not intended to be prescriptive for any specific patient. Appropriate judgement should be exercised by the attending physician before prescribing a course of treatment. N = No reliable antibiotic reference is available for the detected organism. **If an organism is listed in the detected section but not reflected in the sensitivity result table, the organism is either fastidious or failed to grow in vitro and cannot be tested for antibiotic susceptibility.**

PHENOTYPIC SENSITIVITY DETECTED: Amikacin(IV/IM), Amoxicillin / Clavulanate(PO), Ampicillin(PO/IV), Aztreonam(IM/IV), Cefaclor(PO), Cefazolin(IV), Cefepime(IV), Cefixime(PO), Cefotaxime(IM/IV), Cefoxitin(IV), ceftazidime-avibactam(IV), Ceftriaxone(IM/IV), Ciprofloxacin(PO/IV), Doxycycline(PO/IV), Gentamicin(IM/IV), Imipenem(IV), Levofloxacin(PO/IV), Meropenem(IV), Nitrofurantoin(PO), Ofloxacin(PO), Penicillin G(IV), Piperacillin / Tazobactam(IV), Sulfamethoxazole/Trimethoprim(PO/IV), Tetracycline(PO), Tobramycin(IM/IV), Vancomycin(IV)

PHENOTYPIC RESISTANCE DETECTED: Amoxicillin / Clavulanate(PO), Ampicillin(PO/IV), Aztreonam(IM/IV), Cefaclor(PO), Cefazolin(IV), Cefotaxime(IM/IV), Cefoxitin(IV), Doxycycline(PO/IV), Penicillin G(IV), Vancomycin(IV)

ANTIBIOTIC RESISTANCE GENES DETECTED: Extended-Spectrum-β-Lactamase & Carbapenem Resistance, Extended-Spectrum-β-Lactamase*, Methicillin Resistance, Quinolone and Fluoroquinolone Resistance, Sulfonamides Resistance, Tetracycline Resistance

• Testing performed at 12 Spectrum Pointe Drive Lake Forest, CA 92630 | Medical Director: Henry Tsai M.D, P.h.D.

Pre-Prostate Biopsy Rectal Swab Report

Patient Name
PPBRs, Sample

Accession Number
TEDXPBRs24-00025

Procedure Date
11/04/2024

ANTIBIOTIC RESISTANCE GENES NOT DETECTED: Vancomycin Resistant (Glycopeptic antibiotics)

ORGANISM(S) - NOT DETECTED

Bacteria: Acinetobacter baumannii, Aerococcus urinae, Alloscardovia omnicolens, Citrobacter freundii, Citrobacter koseri, Corynebacterium riegellii, Enterobacter aerogenes***, Enterococcus faecalis, Enterococcus faecium, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Mycoplasma hominis, Pantoea agglomerans, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Streptococcus agalactiae, Ureaplasma urealyticum, Viridans Group Streptococci****

FUNGUS: Candida auris, Candida glabrata, Candida parapsilosis, Candida albicans

References:

* Extended Spectrum Beta-Lactamase (ESBL) Resistant genes identified confers resistance across multiple classes of antibiotics including Penicillin derivatives, cephalosporins, monobactams and carbapenems. Refer to the "Resistant Gene Detected" row to identify antibiotics for which the resistance gene may impact. Different ESBLs resistant genes will impact different beta lactam antibiotics in different levels and it is considered in the "Resistant Gene Detected" row for both ESBL (extended-spectrum β -lactamase) and BSBL (broad-spectrum β -lactamase).

** Coagulase Negative Staphylococcus includes Staphylococcus saprophyticus, Staphylococcus epidermidis, Staphylococcus haemolyticus.

*** Klebsiella aerogenes (formerly known as Enterobacter aerogenes)

**** Viridans Streptococci group includes Streptococcus anginosus, Streptococcus oralis and Streptococcus pasteurianus, Streptococcus mitis.

Methodology and Clinical Significance: Laboratory utilizes PCR amplification for the targeted detection of the specified organisms. Detected organisms are reported based on their percentage to the total detected organisms. Detected resistance genes are shown as RGD (Resistance Gene Detected) in the report table. In addition, phenotypic antibiotic susceptibility results are ascertained for the detected organism(s) by employing disk diffusion as a reference method for susceptibility. Antibiotic susceptibility testing is not performed for yeasts or fastidious organisms. For full methodology visit www.emeritusdx.com/methodology.

Disclaimer: This test was developed and its performance characteristics determined by laboratory. It has not been cleared or approved by the US Food and Drug Administration. The FDA has determined that such clearance or approvals is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical testing.

Final Report signed by EmeritusDX Test on 11/05/2024 at 01:23 PM

• Testing performed at 12 Spectrum Pointe Drive Lake Forest, CA 92630 | Medical Director: Henry Tsai M.D, P.h.D.